Phaseline

Companies › Thryv Therapeutics

Thryv Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
THRV-1268–Phase 2Long QT Syndrome (LQTS) 2Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07277582THRV-1268Phase 2Long QT Syndrome (LQTS) 2CardiovascularJun 2027

From the company's SEC filings

Cash of $9m on 2026-06-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kiniksa Pharmaceuticals International Tectonic Therapeutic Nyrada AllRock Bio Zomagen Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.